Grandeur Peak Global Advisors LLC Buys 10,795 Shares of DexCom, Inc. (NASDAQ:DXCM)

Grandeur Peak Global Advisors LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 20.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 63,420 shares of the medical device company’s stock after acquiring an additional 10,795 shares during the quarter. Grandeur Peak Global Advisors LLC’s holdings in DexCom were worth $4,932,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Versant Capital Management Inc bought a new position in shares of DexCom during the 4th quarter worth about $25,000. Private Trust Co. NA boosted its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares in the last quarter. TD Private Client Wealth LLC grew its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth approximately $38,000. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup lifted their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $99.00.

DexCom Trading Down 1.7 %

NASDAQ DXCM opened at $66.14 on Friday. The stock’s 50-day simple moving average is $76.92 and its two-hundred day simple moving average is $76.62. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $25.93 billion, a price-to-earnings ratio of 46.25, a PEG ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 105,009 shares of company stock valued at $8,044,178. Insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.